AstraZeneca Educational Webinar Series
Presented by AADE in association with AstraZeneca-US Medical Affairs, CVMD Division
This educational webinar series is designed to provide the most up-to-date, cutting edge information in diabetes. Each webinar will be presented live and recorded. Archived presentations will be posted on this page for up to 60 days after the live broadcast, so don't miss out!
This webinar series is educational in nature and contains no promotional or product information. CE credit is not available for this activity.
Webinar Schedule for 2019:
All webinars will be held from 1:00-2:00 pm EST
February 13: 2019 Updates on Guidelines in the Management of T2D: Navigating CVOTs and Implications for Treatment
April 10: Cardio-Renal Complications of T2DM: Focus on Heart Failure
June 26: Diabetic Kidney Disease: New Promise for Patients Fighting a Stubborn Nemesis?
August 28: Making Sense of the CVOT Landscape in Type 2 Diabetes (Register now: www.diabeteseducator.org/event/webi190828)
October 23: SGLT-2 Inhibitors in Type 1 Diabetes
December 4: Lipids, HDL, High Triglycerides, and Cardiovascular Risk
Diabetic Kidney Disease: New Promise for Patients Fighting a Stubborn Nemesis?
Originally presented on June 26, 2019 by Robert M. Perkins, MD, MPH, and Curtis Triplitt, PharmD, CDE
After a nearly-two decade period of inactivity and failed trials in diabetic kidney disease (DKD), recent clinical trials have suggested that a new approach to this complication of diabetes may reduce kidney risk. This presentation will review important epidemiologic aspects of DKD, its natural history and pathophysiology, and current treatment approaches. Finally, we will discuss recent clinical trial advances and preview ongoing large, Phase 3 trial programs.
Upon completion of this activity, participants will be able to:
- Identify the major factors which drive kidney disease progression in Type 2 Diabetes
- Identify one new class of agents with potential to improve upon the current standard of care for diabetic kidney disease
Making Sense of the CVOT Landscape in Type 2 Diabetes
Wednesday, August 28, 2019 at 1:00 pm EST
Presented by James A. Ruggles, PhD, and Curtis Triplitt, PharmD, CDE
This presentation aims to put the SGLT-2 Inhibitor and GLP-1 Receptor Agonist Cardiovascular Outcomes Trials (CVOT) into context. We will review study designs, patient populations, and outcomes in patients with established cardiovascular (CV) disease and in patients with risk factors.
Upon completion of this activity, participants will be able to:
- Understand key elements in how CVOTs were designed, including key differences in patient populations and treatment duration.
- Understand post-hoc attempts to understand effects in patients with established disease and in patients with risk factors.
- Describe key takeaways and how these results are impacting treatment guidelines and future directions of research.
Register now: www.diabeteseducator.org/event/webi190828